[en] Arcagen is a clinical study proposing a comprehensive analysis of molecular and clinical characteristics of rare adult solid cancers (11 domains: sarcomas, gynecology, uro-genital, GI, NET, head and neck, thoracic, skin and eyes, CNS and CUP) across Europe, utilizing the EORTC-SPECTA platform with the EURACAN ERN. This study enrolled 1235 advanced stage patients. 893 were evaluable for molecular profiling toward a potential access to personalized therapy.In the 11 different domains, 69.4% (620/893) of patients had actionable mutations, among whom 93 (15% of 620 patients with currently actionable alterations) received targeted- or immune (IO)-therapies. The median overall survival of the patient population without treatment adaptation, with switch to targeted therapy, or immunotherapy was 1.1, 3.3 years, and not reached, respectively.Across Europe, high prevalence and diversity of molecular alterations for rare solid tumors were observed as well as significant disparities regarding access to personalized medicine approaches.
Disciplines :
Oncology
Author, co-author :
Morfouace, M ; Institut Gustave Roussy, Direction de la Recherche Clinique, Villejuif, France. Marie.MORFOUACE@gustaveroussy.fr ; European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium. Marie.MORFOUACE@gustaveroussy.fr
Hoogstoel, F ; European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium
Oliveira, J; Instituto Portugues de Oncologia do Porto Francisco Gentil, Porto, Portugal
Penel, N ; Department of Medical Oncology, Centre Oscar-Lambret, University of Lille, Lille, France ; ULR 2694 - Metrics: Evaluation des technologies de santé et des pratiques médicales, CHU of Lille, University of Lille, Lille, France
Tejpar, S ; UZ Leuven, Leuven, Belgium
Ray-Coquard, I ; Centre Leon Berard, University Claude Bernard Lyon 1, Lyon, France
Peron, J; Department of Medical Oncology, Hospices Civils de Lyon, RESHAPE laboratory, Lyon, France
Pracht, M; Centre Eugene Marquis, Department of Clinical Oncology, Rennes, France
Brasiuniene, B; National Cancer Center of Vilnius University hospital Santaros clinic, Vilnius, Lithuania ; Faculty of Medicine of Vilnius University, Vilnius, Lithuania
Capela, A ; Unidade Local de Saúde de Gaia e Espinho, Vila Nova de Gaia, Portugal
Gennigens, Christine ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Even, C; Head and Neck Department, Gustave Roussy, Villejuif, France
Huang, R; Foundation Medicine Inc., Boston, Massachusetts, USA
Gorlia, T; European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium
Lombardi, G ; Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
Gamulin, M ; University of Zagreb, School of Medicine Department of Clinical Oncology, University Hospital Centre Zagreb, Department of Oncology, Zagreb, Croatia
Licitra, L; Istituto Tumori, Milan, Italy
Girard, N; Institut Curie, Paris, France
Klümpen, H J; University Medical Center Groningen, Department of Medical Oncology, Groningen, The Netherlands
Idbaih, A; Sorbonne Université, AP-HP, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France
Van der Graaf, Wta; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
Blay, J Y ; Centre Leon Berard, University Claude Bernard Lyon 1, Lyon, France. jean-yves.blay@lyon.unicancer.fr
Arcagen is funded by F. Hoffman-La Roche. The EORTC SPECTA platform is supported by Alliance Healthcare. Alliance Healthcare will become Cencora. Fanny Hoogstoel\u2019s work as Fellow at EORTC Headquarters was supported by the EORTC Cancer Research Fund.
Gatta G et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study Lancet Oncol. 2017 18 1022 1039 10.1016/S1470-2045(17)30445-X 28687376
Van Der Graaf WTA et al. Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action Cancer Treat. Rev. 2025 140 10.1016/j.ctrv.2025.103013 40902364 103013
Lenck C et al. The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study Gynecol. Oncol. 2020 157 78 84 10.1016/j.ygyno.2020.02.012 32131977
Gouin F et al. Improved metastatic-free survival after systematic re-excision following complete macroscopic unplanned excision of limb or trunk soft tissue sarcoma Cancers 2024 16 1365 10.3390/cancers16071365 38611043 11010862
Blay JY et al. Improved nationwide survival of sarcoma patients with a network of reference centers Ann. Oncol. 2024 35 351 363 10.1016/j.annonc.2024.01.001 38246351
Blay J-Y et al. Surgery in reference centers improves survival of sarcoma patients: a nationwide study Ann. Oncol. 2019 30 1143 1153 10.1093/annonc/mdz124 31081028 6637376
Blay J-Y et al. Improved survival using specialized multidisciplinary board in sarcoma patients Ann. Oncol. 2017 28 2852 2859 10.1093/annonc/mdx484 29117335 5834019
Othus, M. et al. Outcomes of patients with rare cancers treated with combination immune checkpoint inhibitors with and without prior anti-PD-1/L1 exposure (NCI/SWOG S1609). JCO Oncol. Adv.2, e2500110 (2025).
Krämer A et al. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Ann. Oncol. 2023 34 228 246 10.1016/j.annonc.2022.11.013 36563965
Westphalen CB et al. ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice Ann. Oncol. 2025 36 614 625 10.1016/j.annonc.2025.02.009 40194904
Westphalen CB et al. The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development Ann. Oncol. 2024 35 936 953 10.1016/j.annonc.2024.07.730 39187421
Mosele MF et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group Ann. Oncol. 2024 35 588 606 10.1016/j.annonc.2024.04.005 38834388
Mateo J et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) Ann. Oncol. 2018 29 1895 1902 10.1093/annonc/mdy263 30137196 6158764
Nakhaei-Rad S Soleimani Z Vahedi S Gorjinia Z Testicular germ cell tumors: genomic alternations and RAS-dependent signaling Crit. Rev. Oncol./Hematol. 2023 183 103928 10.1016/j.critrevonc.2023.103928 36717007
Ní Leathlobhair M et al. Genomic landscape of adult testicular germ cell tumours in the 100,000 Genomes Project Nat. Commun. 2024 15 2024NatCo.15.9247T 10.1038/s41467-024-53193-6 39461959 11513037 9247
Hodroj K et al. Molecular characterization of ovarian yolk sac tumor (OYST) Cancers 2021 13 220 10.3390/cancers13020220 33435376 7826864
Moore, J. A. et al. Pan-cancer analysis of copy-number features identifies recurrent signatures and a homologous recombination deficiency biomarker to predict poly (ADP-Ribose) polymerase inhibitor response. JCO Precis. Oncol.7, e2300093 (2023).
Richardson DL et al. Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2 and a Scar-based HRD signature in real-world practice Clin. Cancer Res. 2024 30 4644 4653 10.1158/1078-0432.CCR-24-1225 39078736 11474169
Anbil, S. et al. LODESTAR: a single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes. JCO Precis. Oncol.9, e2500090 (2025).
Casolino R et al. The WHO global landscape of cancer clinical trials Nat. Med. 2025 31 2901 2912 10.1038/s41591-025-03926-x 40926101
Van Der Laan P et al. The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcoma ESMO Open 2025 10 10.1016/j.esmoop.2025.105287 40505420 12192325 105287
Morfouace M et al. Abstract 7470: Extensive genome sequencing on tissue vs large ctDNA panel: what clinical impact? Cancer Res. 2025 85 7470 7470 10.1158/1538-7445.AM2025-7470
Bailey MH et al. CompreheNsive Characterization Of Cancer Driver Genes And Mutations Cell 2018 173 371 385.e18 10.1016/j.cell.2018.02.060 29625053 6029450
Shah Y et al. Pan-cancer analysis reveals molecular patterns associated with age Cell Rep. 2021 37 10.1016/j.celrep.2021.110100 34879281 110100
Colombo E et al. Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study ESMO Open 2025 10 10.1016/j.esmoop.2025.105856 41167086 12607031 105856
Rae S et al. Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders J. Cancer Res. Clin. Oncol. 2023 149 16355 16363 10.1007/s00432-023-05365-y 37702806 10645649
Bayle A et al. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study Ann. Oncol. 2023 34 389 396 10.1016/j.annonc.2023.01.008 36709039
Trédan O et al. Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial Nat. Med 2025 31 1502 1508 10.1038/s41591-025-03613-x 40195451 12092287
Padovan M et al. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis Eur. J. Cancer 2023 191 10.1016/j.ejca.2023.112959 37481865 112959
Verkerk K et al. The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) ESMO Open 2025 10 10.1016/j.esmoop.2024.104112 39778224 11760820 104112
Verlingue L et al. The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST AO 2024 63 411 417 10.2340/1651-226X.2024.32745
Marchetti P et al. Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial Nat. Med 2025 31 3514 3523 10.1038/s41591-025-03918-x 41023484 12532583
Blay J-Y et al. Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN Lancet Reg Health Eur. 2024 39 10.1016/j.lanepe.2024.100861 38384730 10879812 100861
Brown S et al. Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies JAMA Oncol. 2022 8 287 10.1001/jamaoncol.2021.5153 34734967 9190030
Jin Y Ton TGN Incerti D Hu S Left truncation in linked data: A practical guide to understanding left truncation and applying it using SAS and R Pharm. Stat. 2023 22 194 204 10.1002/pst.2257 35843723
